• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Ardea Biosciences, Inc. - Product Pipeline Review - Q1 2011 Product Image

Ardea Biosciences, Inc. - Product Pipeline Review - Q1 2011

  • ID: 1447053
  • March 2011
  • 58 pages
  • Global Markets Direct

Ardea Biosciences, Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Ardea Biosciences, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Ardea Biosciences, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ardea Biosciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination READ MORE >



List of Tables
List of Figures
Ardea Biosciences, Inc. Snapshot
Ardea Biosciences, Inc. Overview
Key Information
Key Facts
Ardea Biosciences, Inc. – Research and Development Overview
Key Therapeutic Areas
Ardea Biosciences, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Ardea Biosciences, Inc. – Pipeline Products Glance
Ardea Biosciences, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Ardea Biosciences, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Ardea Biosciences, Inc. – Drug Profiles
RDEA 806
Product Description
Mechanism of Action
R&D Progress
RDEA594
Product Description
Mechanism of Action
R&D Progress
RDEA594 + Allopurinol
Product Description
Mechanism of Action
R&D Progress
RDEA 436
Product Description
Mechanism of Action
R&D Progress
RDEA594 + Febuxostat
Product Description
Mechanism of Action
R&D Progress
RDEA684
Product Description
Mechanism of Action
R&D Progress
Ardea Biosciences, Inc. – Pipeline Analysis
Ardea Biosciences, Inc. – Pipeline Products by Therapeutic Class
Ardea Biosciences, Inc. - Pipeline Products By Target
Ardea Biosciences, Inc. – Pipeline Products by Route of Administration
Ardea Biosciences, Inc. – Pipeline Products by Molecule Type
Ardea Biosciences, Inc. – Recent Pipeline Updates
Ardea Biosciences, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Iseganan
Ardea Biosciences, Inc. – Company Statement
Ardea Biosciences, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Jun 18, 2010: Ardea Presents Positive Phase II Data On RDEA594 For Treatment Of Hyperuricemia And Gout At EULAR Annual European Congress
Jun 18, 2010: Ardea Presents Positive Phase II Data On RDEA594 For Treatment Of Hyperuricemia And Gout At EULAR Annual European Congress
Jun 18, 2010: Ardea Presents Interim Results From Phase Ib Study Of RDEA594 In Combination With Allopurinol For Treatment Of Hyperuricemia And Gout At EULAR Annual European Congress
Jun 18, 2010: Ardea Presents Interim Results From Phase Ib Study Of RDEA594 In Combination With Allopurinol For Treatment Of Hyperuricemia And Gout At EULAR Annual European Congress
Jun 18, 2010: Ardea Presents Data From Proof-Of-Concept Study Examining Combination Of RDEA594 And Febuxostat For Treatment Of Hyperuricemia And Gout At EULAR Annual European Congress
Jun 18, 2010: Ardea Presents Data From Proof-Of-Concept Study Examining Combination Of RDEA594 And Febuxostat For Treatment Of Hyperuricemia And Gout At EULAR Annual European Congress
May 13, 2010: Ardea Biosciences To Present Additional Data On Gout Program At Annual European Congress Of Rheumatology
Mar 31, 2010: Ardea Announces Positive Top-Line Results From Phase IIb Study Of RDEA594 For Treatment Of Hyperuricemia In Gout Patients
Mar 31, 2010: Ardea Announces Positive Top-Line Results From Phase IIb Study Of RDEA594 For Treatment Of Hyperuricemia In Gout Patients
Jan 07, 2010: Ardea Biosciences Announces Phase 2A Study Results Of RDEA594 For The Treatment Of Hyperuricemia And Gout
Financial Deals Landscape
Ardea Biosciences, Inc., Deals Volume Summary, 2004 to YTD 2011
Ardea Biosciences, Inc., Deals Summary By Region, 2004 to YTD 2011
Ardea Biosciences, Inc., Deals Summary, 2004 to YTD 2011
Ardea Biosciences, Inc. Detailed Deal Summary
Asset Purchase
Ardea Biosciences Acquires Intellectual Property And Other Assets From Valeant Pharmaceuticals
Equity Offering
Ardea Biosciences Completes Private Placement Of $31 Million
Ardea Biosciences Completes Private Placement $40 Million
Intrabiotics Pharmaceuticals Completes Public Offering Of $44.85 Million
Hadassah Medical Forms Joint Venture With BWH And Harvard Medical
Licensing Agreements
Ardea Biosciences Enters Into License Agreement With Bayer HealthCare
BioLineRx Enters Into Licensing Agreement With Yissum Research Development And Hadasit
Ardea Biosciences Terminates Licensing Agreement With Regents Of The University Of California
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Ardea Biosciences, Inc. – Pipeline by Therapy Area and Indication, 2011
Ardea Biosciences, Inc. – Pipeline by Stage of Development, 2011
Ardea Biosciences, Inc. – Monotherapy Products in Pipeline, 2011
Ardea Biosciences, Inc. – Combination Treatment Modalities in Pipeline, 2011
Ardea Biosciences, Inc. - Phase II, 2011
Ardea Biosciences, Inc. - Phase I, 2011
Ardea Biosciences, Inc. - Pipeline By Therapeutic Class, 2011
Ardea Biosciences, Inc. - Pipeline By Target, 2011
Ardea Biosciences, Inc. – Pipeline By Route of Administration, 2011
Ardea Biosciences, Inc. – Pipeline By Molecule Type, 2011
Ardea Biosciences, Inc. – Recent Pipeline Updates, 2011
Ardea Biosciences, Inc. - Discontinued Pipeline Products, 2010
Ardea Biosciences, Inc., Deals Summary, 2004 to YTD 2011
Ardea Biosciences, Inc., Deals Summary by Region, 2004 to YTD 2011
Ardea Biosciences, Inc., Deals Summary, 2004 to YTD 2011

List of Figures
Ardea Biosciences, Inc. – Pipeline by Therapy Area and Indication, 2011
Ardea Biosciences, Inc. – Pipeline by Stage of Development, 2011
Ardea Biosciences, Inc. – Monotherapy Products in Pipeline, 2011
Ardea Biosciences, Inc. – Combination Treatment Modalities in Pipeline, 2011
Ardea Biosciences, Inc. – Pipeline By Therapeutic Class, 2011
Ardea Biosciences, Inc. - Pipeline By Target, 2011
Ardea Biosciences, Inc. – Pipeline By Molecule Type, 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos